To market, to market - 1995

被引：29
作者：
Cheng, XM [1 ]
机构：
[1] WARNER LAMBERT PARKE DAVIS, PARKE DAVIS PHARMACEUT RES DIV, ANN ARBOR, MI 48105 USA
来源：
ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 31 | 1996年 / 31卷
关键词：
D O I：
10.1016/S0065-7743(08)60473-X
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
[No abstract available]
引用
收藏
页码：337 / 355
页数：19
相关论文
共 129 条
[1]  
ABRAMOWICZ M, 1995, MED LETT DRUGS THER, V37, P75
[2]   EFFICACY AND SAFETY PROFILE OF GEMCITABINE IN NON-SMALL-CELL LUNG-CANCER - A PHASE-II STUDY [J].
ABRATT, RP ;
BEZWODA, WR ;
FALKSON, G ;
GOEDHALS, L ;
HACKING, D ;
RUGG, TA .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (08) :1535-1540
[3]  
Agarwal M. B., 1992, Drugs of Today, V28, P107
[4]  
ALLISON AC, 1993, AGENT ACTION SUPPL, V44, P165
[5]   IMMUNOSUPPRESSIVE AND OTHER EFFECTS OF MYCOPHENOLIC-ACID AND AN ESTER PRODRUG, MYCOPHENOLATE MOFETIL [J].
ALLISON, AC ;
EUGUI, EM .
IMMUNOLOGICAL REVIEWS, 1993, 136 :5-28
[6]  
ALSAKA K, 1992, JPN J PHARMACOL, V59, P489
[7]  
[Anonymous], BREAST CANC RES TREA
[8]  
ASANO T, 1987, J PHARMACOL EXP THER, V241, P1033
[9]  
ASANO T, 1990, METHOD FIND EXP CLIN, V12, P443
[10]   PRECLINICAL PHARMACOLOGY OF DOCETAXEL [J].
BISSERY, MC .
EUROPEAN JOURNAL OF CANCER, 1995, 31A :S1-S6
12345678910